Sustainability reporting in US biotech in 2026: who still publishes, and what survives being checked

We screened 481 US-listed biotechs and read all 30 current sustainability reports.

There are 481 US-listed, actively traded biotech companies, and we went through every one of them looking for disclosure. 330 do not publish anything. No report, ESG page, or a section mentioned in the annual report.  Thirty hold a current report with 2025 data.

The field you are compared against is not the one you probably picture. Simply publishing Scope 1 and Scope 2 with a base year beside them would put you in a group of nine.

Whether you choose to report or not, a rater with no data from you still publishes a score, a pharma customer still sends its EcoVadis request on its own schedule, and an acquirer's diligence still reads whatever happens to be public on the day it looks.

Of the 30 published reports, most of what looks like disclosure turns out to be a word with no number behind it. Twenty-one of the 30 name Scope 1 and Scope 2, and nine state the base year their reductions are measured from. Twenty-one use the word assurance, ten describe obtaining it over emissions, and six say who did the work.

The full benchmark sets out the five levels every report sits on, what those four claims mean once you check them, why you cannot compare any of these reports from the cover, and what to do next depending on whether you publish today or have never started.